BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/12/2025 8:18:29 AM | Browse: 358 | Download: 708
Publication Name World Journal of Experimental Medicine
Manuscript ID 107020
Country Lebanon
ISSN 2220-315x (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Minireviews
Article Title Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases
Manuscript Source Unsolicited Manuscript
All Author List Elie Chamchoum, Nadia Katrib, Nicolas Nassif, Yara Ratel and Mohamad Ali Rida
ORCID
Author(s) ORCID Number
Elie Chamchoum http://orcid.org/0009-0008-4777-9089
Nadia Katrib http://orcid.org/0009-0003-7304-168X
Nicolas Nassif http://orcid.org/0009-0000-3526-6165
Yara Ratel http://orcid.org/0009-0004-5719-7593
Mohamad Ali Rida http://orcid.org/0000-0001-9858-2923
Funding Agency and Grant Number
Corresponding Author Mohamad Ali Rida, Assistant Professor, MD, Department of Internal Medicine, Clemenceau Medical Center, Clemenceau, Beirut 1, Lebanon. mohamad.ali.rida@gmail.com
Key Words Glucagon-like peptide-1 agonists; Osteoarthritis; Rheumatoid arthritis; Psoriatic arthritis; System lupus erythematosus; Inflammation
Core Tip Growing evidence suggests that glucagon-like peptide-1 and its receptor agonists could be an effective treatment option not only for metabolic disorders but also for a range of autoimmune and inflammatory diseases. They may protect cartilage and reduce joint inflammation, lower the levels of inflammatory cytokines, helping prevent further joint damage and address both the metabolic and inflammatory aspects, reducing cytokine levels and potentially improving disease outcomes.
Publish Date 2025-08-12 08:18
Citation

Chamchoum E, Katrib N, Nassif N, Ratel Y, Rida MA. Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases. World J Exp Med 2025; 15(3): 107020

URL https://www.wjgnet.com/2220-315X/full/v15/i3/107020.htm
DOI https://dx.doi.org/10.5493/wjem.v15.i3.107020
Full Article (PDF) WJEM-15-107020-with-cover.pdf